Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06414300 Phase 1 in healthy volunteers
NCT06659250Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing PF-06414300 with Placebo (2 arms). Primary endpoints: Adverse Events, Serious Adverse Events and 3 more. Started Sep 2024; status: completed.
02
Drugs
PF-06414300
Beyond the preview
Go deeper on NCT06659250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659250.